NCT07482540

Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery

The Prophylactic Role of Dexmedetomidine Drug in Reducing Early Postoperative New Onset Atrial Fibrillation After Mitral Valve Surgery - a Randomized Controlled Clinical Trial

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 140 (estimated)
• Sponsor: Ain Shams University · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

Recently, dexmedetomidine has been suggested as an alternative agent for sedation in tachyarrhythmias due to its antiarrhythmic properties through decreased catecholamine release, prolonged refractory period, and increased vagal tone. In addition, dexmedetomidine is a highly selective agonist that does not interact with the gamma-aminobutyric acid (GABA) receptors. Thus, its analgesic properties are opioid sparing, which is unique among traditional ICU sedatives and avoids the issue of respiratory depression with over-sedation. Our aim: To evaluate the potential prophylactic effect of perioperative dexmedetomidine in reducing the incidence of early postoperative new onset atrial fibrillation following mitral valve surgery.

Conditions

• New Onset
• Atrial Fibrillation

Interventions

Type	Name	Description
DRUG	Dexmedetomidine	Drug infusion to reduce postoperative atrial fibrillation
OTHER	Saline	Normal saline infusion for placebo

Timeline

• Start date: 2026-06-01
• Primary completion: 2027-05-31
• Completion: 2027-12-31
• First posted: 2026-03-19
• Last updated: 2026-03-19